Mitsubishi Tanabe Pharma Corp (4508.T)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2015||Executive President, President, Representative Director|
|2017||Chief Compliance Officer, Executive Officer, Director of Legal Affairs & Intellectual Property|
|61||2017||Senior Managing Executive Officer, Chief Director of CMC, Representative Director|
|62||2016||Managing Executive Officer, Chief Director of Sales, Director|
|60||2017||Managing Executive Officer, Chief Director of Drug Fostering & Evolution, Director|
- BRIEF-Dyadic International Announces R&D Collaboration With Mitsubishi Tanabe Pharma Corp
- Mobileye deal boosts Israeli high-tech exits to $23 bln in 2017
- BRIEF-Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
- BRIEF-Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
- BRIEF-Mitsubishi Tanabe Pharma completes purchase of NeuroDerm